動脈粥狀硬化治療藥物市場規模、佔有率和成長分析：按藥物類別、給藥途徑、分銷管道和地區分類－2026-2033年產業預測

2024 年全球動脈硬化治療市場價值為 354.3 億美元，預計到 2033 年將從 2025 年的 365 億美元成長至 462.7 億美元，在預測期（2026-2033 年）內複合年成長率為 3.01%。

全球動脈粥狀硬化治療市場深受保險報銷體系改革和基於價值的定價模式的影響，這些改革影響著病患的就醫途徑和製藥公司的策略。保險公司將健保覆蓋與臨床療效掛鉤，加速了創新治療方法有效降低心肌梗塞的發生率。這種現象形成了一個良性循環：可靠的臨床數據帶來更高的報銷額度，進而刺激進一步的研發。在多項研究顯示心血管事件顯著減少之後，醫療系統正轉向風險共擔協議，這不僅提高了收入，也加速了市場擴張，尤其是在發展中地區。市場正不斷發展，從傳統的他汀類藥物轉向先進的降血脂療法，凸顯了科學進步和疾病盛行率上升對市場的影響。此外，人工智慧驅動的藥物發現正在簡化標靶治療的研發流程，從而促進市場環境的更快、更有效率。

全球動脈粥狀硬化治療市場的成長要素

心血管疾病發病率的不斷上升顯著推動了對靶向動脈斑塊積聚的有效治療方法的需求。隨著醫療專業人員日益認知到動脈粥狀硬化是一個重要的危險因素，降血脂藥和抗發炎藥物的處方量也大幅增加。患者對疾病影響的認知不斷提高，促使人們更加渴望早期干預，而醫療系統也更加重視預防措施，以減輕長期的醫療負擔。這種環境為製藥公司提供了創新和推出符合臨床標準並能改善患者預後的新治療方法的機遇，從而促進了市場投資和合作的增加。

全球動脈硬化治療市場面臨的限制因素

全球動脈粥狀硬化治療市場面臨許多限制因素，主要原因是創新治療方法高成本。這阻礙了預算緊張的醫療系統獲得治療的機會。保險公司通常要求在批准報銷前進行全面的醫療技術評估，導致新治療方法的推廣應用延遲。患者往往需要承擔高額的自付費用，迫使醫療專業人員優先選擇療效相近但價格較低廉的老藥。製藥公司面臨定價壓力，既要維持利潤率，也要確保價格合理，最終導致市場成長放緩，醫療機構不願採用高成本治療方法。

全球動脈硬化治療藥物市場趨勢

在全球動脈粥狀硬化治療市場中，精準基因體學的進步正推動著一場重大變革。識別與斑塊形成相關的患者特異性基因突變的能力，使得藥物研發人員能夠開發出標靶治療，從分子層面解決疾病的根本原因。這種模式轉移使得早期療育和個人化治療方案成為可能，從而使醫療服務提供者能夠根據個別風險狀況量身定做治療方法，並在臨床症狀出現之前阻止疾病進展。學術合作和生物技術創新的蓬勃發展，正推動市場從廣譜降脂藥物轉向高選擇性生物製藥，從而重塑動脈粥狀硬化的治療策略。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球動脈粥狀硬化治療藥物市場規模：依藥物類別分類

• 他汀類藥物
• PCSK9抑制劑
• 貝培多酸和ACL抑制劑
• 抗血小板藥物和抗凝血劑
• Omega-3脂肪酸衍生物
• 基於RNA的治療方法
• 其他

全球動脈粥狀硬化治療市場規模：依給藥途徑分類

• 口服製劑
• 注射藥物

全球動脈粥狀硬化治療市場規模：依通路分類

• 醫院藥房
• 零售藥局和藥房
• 網路藥房

全球動脈粥狀硬化治療市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc.
• AstraZeneca plc
• Merck & Co. Inc.
• Amgen Inc.
• Sanofi SA
• Regeneron Pharmaceuticals Inc.
• Novartis AG
• Eli Lilly and Company
• Bristol Myers Squibb Company
• Esperion Therapeutics Inc.
• Kowa Company Ltd.
• Daiichi Sankyo Company Limited
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson
• AbbVie Inc.
• Viatris Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Ionisl Pharma

結論與建議

Global Atherosclerosis Drugs Market size was valued at USD 35.43 Billion in 2024 and is poised to grow from USD 36.5 Billion in 2025 to USD 46.27 Billion by 2033, growing at a CAGR of 3.01% during the forecast period (2026-2033).

The global atherosclerosis drugs market is significantly influenced by reimbursement reforms and value-based pricing, impacting patient access and manufacturer strategies. Insurers linking coverage to clinical outcomes encourage the adoption of innovative therapies that effectively reduce myocardial infarction rates, exemplified by next-generation agents. This phenomenon fosters a cycle where robust clinical data leads to enhanced reimbursements, facilitating further research and development. Studies demonstrating substantial reductions in cardiac events have prompted health systems to engage in risk-sharing agreements, enhancing revenue and accelerating market expansion, particularly in developing regions. The market evolves continuously, transitioning from traditional statins to advanced lipid-lowering therapies, highlighting the influence of scientific advancements and increased disease prevalence. Additionally, AI-driven drug discovery is streamlining the development of targeted therapies, promoting a faster and more efficient market landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Atherosclerosis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Atherosclerosis Drugs Market Segments Analysis

Global atherosclerosis drugs market is segmented by drug class, route of administration, distribution channel and region. Based on drug class, the market is segmented into Statins, PCSK9 Inhibitors, Bempedoic Acid and ACL Inhibitors, Antiplatelet and Anticoagulant Agents, Omega-3 Fatty Acid Derivatives, RNA-Based Therapies and Others. Based on route of administration, the market is segmented into Oral Formulations and Injectable Formulations. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Drug Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Atherosclerosis Drugs Market

The growing incidence of cardiovascular diseases significantly boosts the demand for effective treatments targeting plaque buildup in arteries. As medical professionals increasingly identify atherosclerosis as a critical risk factor, there is a notable rise in the prescription of lipid-lowering and anti-inflammatory medications. Enhanced patient awareness about the implications of the disease further drives individuals to seek timely interventions, while healthcare systems place a strong emphasis on preventive measures to alleviate long-term healthcare burdens. This environment creates fertile ground for pharmaceutical companies to innovate and launch new therapies that meet clinical standards and improve patient outcomes, fostering increased investment and collaboration within the market.

Restraints in the Global Atherosclerosis Drugs Market

The global market for atherosclerosis drugs faces significant constraints primarily due to the high costs associated with innovative therapies, which hampers accessibility in health systems that operate under tight budgetary limits. Payers typically demand thorough health technology assessments prior to approving reimbursement, resulting in a lag in the adoption of new treatments. Patients often incur substantial out-of-pocket expenses, leading healthcare professionals to prioritize older, more affordable medications that may offer similar therapeutic benefits. As manufacturers navigate pricing pressures, they struggle to maintain profit margins while ensuring affordability, ultimately leading to slower market growth and a reluctance among healthcare providers to adopt costly treatment regimens.

Market Trends of the Global Atherosclerosis Drugs Market

The Global Atherosclerosis Drugs market is experiencing a notable transformation driven by advancements in precision genomics. The ability to identify patient-specific genetic variants associated with plaque formation is leading pharmaceutical developers to create targeted therapeutics that address the disease at its molecular roots. This paradigm shift facilitates earlier intervention and personalized treatment regimens, enabling healthcare providers to tailor therapies to individual risk profiles and potentially prevent disease progression prior to the onset of clinical symptoms. The surge in academic collaborations and biotech innovation is steering the market away from traditional broad-spectrum lipid-lowering agents toward a new era of highly selective biologics, thereby reshaping treatment strategies for atherosclerosis.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Atherosclerosis Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Statins
• PCSK9 Inhibitors
• Bempedoic Acid and ACL Inhibitors
• Antiplatelet and Anticoagulant Agents
• Omega-3 Fatty Acid Derivatives
• RNA-Based Therapies
• Others

Global Atherosclerosis Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral Formulations
• Injectable Formulations

Global Atherosclerosis Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies and Drug Stores
• Online Pharmacies

Global Atherosclerosis Drugs Market Size & CAGR (2026-2033)

• North America (Drug Class, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route of Administration, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Esperion Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kowa Company Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionisl Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations